FI109905B - Förfarande för framställning av antivirala hydroximetyl(metylencyklopentyl)puriner och -pyrimidiner - Google Patents

Förfarande för framställning av antivirala hydroximetyl(metylencyklopentyl)puriner och -pyrimidiner Download PDF

Info

Publication number
FI109905B
FI109905B FI914928A FI914928A FI109905B FI 109905 B FI109905 B FI 109905B FI 914928 A FI914928 A FI 914928A FI 914928 A FI914928 A FI 914928A FI 109905 B FI109905 B FI 109905B
Authority
FI
Finland
Prior art keywords
formula
phenylmethoxy
compound
dichloromethane
methyl
Prior art date
Application number
FI914928A
Other languages
English (en)
Finnish (fi)
Other versions
FI914928A0 (fi
FI914928A (fi
Inventor
Robert Zahler
William A Slusarchyk
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24400159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI109905(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of FI914928A0 publication Critical patent/FI914928A0/fi
Publication of FI914928A publication Critical patent/FI914928A/fi
Application granted granted Critical
Publication of FI109905B publication Critical patent/FI109905B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Tires In General (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Claims (6)

1. Förfarande för framställning av antivirala hydroximetyl(metylencyklopentyl)purin- eller -pyrimidin-5 föreningar med formeln (1) eller farmaceutiskt godtagbara salter därav, HYH HOCH2v/ \ Xri 10 Λη (1) \ H H-O H H i vilken formel Rx är: 15 ί (/Χλ <*r I N NH2 , I I 11 /
20 I * * • t · nh2 . : : I * o
25 PrrR2 Jv-R I Jj eller I |p 2 •/Λ cf f cfy » · * * · * » · !..* 30 där R, är väte, fluor, klor, brom eller • · * H\ /Ra : : c -a*- cr ^ \h 35 (trans) Iitit I 75 109905 där R3 är klor, brom eller jod; kännetecknat därav, att a) en förening raed formeln 5 V PO 10 där P är en skyddsgrupp, säsom bensyl, trityl, substitue-rad trityl eller en silylgrupp, omsätts med en förening, som har formeln
15 RjH som är eventuellt skyddad, för erhällande av en mellanpro-dukt, som har formeln 20 /7~\\ H° \2r h2coh2cv^aRi v : P-0 25 M « » b) mellanprodukten, som erhällits i steg (a) , oxi- • · ...^ deras för erhällande av en mellanprodukt med formeln I t i O V:J 30 (^h2c-°»2c\X^+Ri ... \ P-0 35 c) mellanprodukten, som erhällits i steg (b) , om- • sätts med ett metyleringsmedel för erhällande av en mel lanprodukt, som har formeln 76 1099C5 H H <^V-0H2C^X^ P—0s d) bensylskyddsgruppen, skyddgrupp P och vilken som heist skyddsgrupp i Rx avlägsnas för erhällande av en 10 önskad förening med formeln (1) .
2. Förfarande enligt patentkrav 1, känne-t e c k n a t därav, att man framställer en förening med formeln (1), där Rx är: 15. nh2 N ΝΉ <;I a eller i j) I N NH2 CT N
1 I 20 • · • · • · · • · • t • · · n $ · • II» • · I I * I · · » · • » · I Il • I I < · • t • » * » • · · » I II· • · I t · • * * » I
FI914928A 1990-10-18 1991-10-18 Förfarande för framställning av antivirala hydroximetyl(metylencyklopentyl)puriner och -pyrimidiner FI109905B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59956890A 1990-10-18 1990-10-18
US59956890 1990-10-18

Publications (3)

Publication Number Publication Date
FI914928A0 FI914928A0 (fi) 1991-10-18
FI914928A FI914928A (fi) 1992-04-19
FI109905B true FI109905B (sv) 2002-10-31

Family

ID=24400159

Family Applications (1)

Application Number Title Priority Date Filing Date
FI914928A FI109905B (sv) 1990-10-18 1991-10-18 Förfarande för framställning av antivirala hydroximetyl(metylencyklopentyl)puriner och -pyrimidiner

Country Status (28)

Country Link
US (1) US5206244A (sv)
EP (1) EP0481754B1 (sv)
JP (1) JP2994117B2 (sv)
KR (1) KR0160523B1 (sv)
CN (1) CN1030916C (sv)
AT (1) ATE157095T1 (sv)
AU (1) AU634423B2 (sv)
BR (1) BR1100846A (sv)
CA (1) CA2053339C (sv)
CY (2) CY2063B1 (sv)
DE (3) DE122006000069I1 (sv)
DK (1) DK0481754T3 (sv)
ES (1) ES2104673T3 (sv)
FI (1) FI109905B (sv)
GR (1) GR3025395T3 (sv)
HK (1) HK1001343A1 (sv)
HU (1) HU213207B (sv)
IE (1) IE913451A1 (sv)
IL (1) IL99755A (sv)
LU (1) LU91275I2 (sv)
NL (1) NL300241I1 (sv)
NO (2) NO179906C (sv)
NZ (1) NZ240053A (sv)
PL (1) PL169403B1 (sv)
PT (1) PT99281B (sv)
RU (1) RU2037496C1 (sv)
SG (1) SG70958A1 (sv)
ZA (1) ZA917894B (sv)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0630897A3 (en) * 1993-06-25 1995-03-01 Bristol Myers Squibb Co 3-hydroxy-4-hydroxymethyl-2-methylene-cyclopentyl purines and pyrimidines.
WO1996001834A1 (fr) * 1994-07-12 1996-01-25 Yamasa Corporation 2'-desoxy-2'-(methylidene substitue ou non substitue)-4'-thionucleoside
WO1996019478A1 (en) * 1994-12-19 1996-06-27 Novartis Ag 6'-substituted carbocyclic nucleosides
GB9520363D0 (en) * 1995-10-05 1995-12-06 Chiroscience Ltd Compounds
AU4090697A (en) * 1996-09-03 1998-03-26 Bristol-Myers Squibb Company Improved process for preparing the antiviral agent {1s-(1alpha, 3alpha, 4beta)}-2-amino-1,9-dihydro-9-{4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl}-6h-purin-6-one
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
MXPA01001507A (es) * 1998-08-10 2003-09-10 Novirio Pharmaceuticals Ltd °l-2'desoxi-nucleosidos para el tratamiento de hepatitis b.
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
CN1813753B (zh) * 2000-02-29 2010-04-07 布里斯托尔-迈尔斯斯奎布公司 低剂量艾替开韦制剂及其应用
IL150447A0 (en) * 2000-02-29 2002-12-01 Bristol Myers Squibb Co Pharmaceutical compositions containing entecavir
WO2001067772A2 (en) * 2000-03-09 2001-09-13 Videoshare, Inc. Sharing a streaming video
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
US7153691B2 (en) * 2002-11-13 2006-12-26 G6 Science Corp. Method of identifying and assessing DNA euchromatin in biological cells for detecting disease, monitoring wellness, assessing bio-activity, and screening pharmacological agents
IN2012DN00606A (sv) * 2002-12-11 2015-06-12 Bristol Mayers Squibb Company
TW200540175A (en) * 2004-06-04 2005-12-16 Bristol Myers Squibb Co Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
US7511139B2 (en) * 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN100379736C (zh) * 2005-05-13 2008-04-09 上海仲夏化学有限公司 恩替卡韦的制备方法
CN1699366A (zh) * 2005-06-03 2005-11-23 北京市典范科技有限责任公司 嘌呤衍生物
CN1907987B (zh) * 2005-08-03 2010-05-05 江苏正大天晴药业股份有限公司 恩地卡韦酸加成盐及其制备方法和用途
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
CN101016299B (zh) * 2006-02-09 2010-05-12 北京典范科技有限责任公司 制备嘌呤衍生物的新方法
CN101130542B (zh) * 2006-08-24 2010-08-04 江苏正大天晴药业股份有限公司 抗病毒核苷类似物的合成方法
CN101210015B (zh) * 2006-12-26 2010-09-22 上海国创医药有限公司 一种乙肝治疗药物恩替卡韦的制备方法
CN101245068A (zh) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 结晶型态的恩替卡韦及其制备方法和其药物组合物及用途
CN101074217B (zh) * 2007-04-04 2010-11-24 北京精华耀邦医药科技有限公司 通过制备色谱分离得到高纯度恩替卡韦关键中间体的方法
RU2443703C2 (ru) 2007-06-18 2012-02-27 Саншайн Лейк Фарма Ко., Лтд Бром-фенил замещенные тиазолилдигидропиримидины
US20090076038A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched entecavir
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
SG172363A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Synthesis of purine nucleosides
WO2010075517A2 (en) * 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
KR101150254B1 (ko) * 2008-12-26 2012-06-12 한미사이언스 주식회사 신규 중간체 및 이를 활용한 엔테카비르 제조방법
CN101531660B (zh) * 2009-04-14 2012-07-04 安徽贝克联合制药有限公司 一种恩替卡韦一水合物的工业化生产工艺
WO2011046303A2 (en) 2009-10-12 2011-04-21 Hanmi Holdings Co., Ltd. Novel method for preparing entecavir and intermediate used therein
US9700560B2 (en) * 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CN101759698B (zh) * 2009-12-15 2012-01-18 上海医药集团股份有限公司 一种恩替卡韦的制备方法
US8481728B2 (en) * 2010-02-16 2013-07-09 Scinopharm Taiwan, Ltd. Process for preparing entecavir and its intermediates
AP3515A (en) 2010-03-31 2016-01-11 Gilead Pharmasset Llc Nucleoside phosphoramidates
CA2705953C (en) * 2010-05-31 2018-05-01 Alphora Research Inc. Carbanucleoside synthesis and intermediate compounds useful therein
EP2474548A1 (en) 2010-12-23 2012-07-11 Esteve Química, S.A. Preparation process of an antiviral drug and intermediates thereof
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
CN102491960A (zh) * 2011-11-16 2012-06-13 福建广生堂药业股份有限公司 一种合成恩替卡韦的中间体及其制备方法和应用
EP2597096A1 (en) 2011-11-24 2013-05-29 Esteve Química, S.A. Process for preparing entecavir and intermediates thereof
CN103304375B (zh) * 2012-03-12 2017-04-12 浙江奥翔药业股份有限公司 恩替卡韦的合成中间体及其制备方法
AU2013257951A1 (en) 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
WO2015014737A1 (en) 2013-07-29 2015-02-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Multilayer tablet formulations comprising tenofovir and entecavir
WO2015051900A1 (en) 2013-10-08 2015-04-16 Pharmathen S.A. Process for the preparation of entecavir through novel intermediates
KR101640503B1 (ko) * 2015-04-15 2016-07-18 동방에프티엘(주) 엔테카비르 일수화물의 개선된 제조방법
KR101640504B1 (ko) * 2015-04-15 2016-07-18 동방에프티엘(주) 엔테카비르 일수화물의 제조방법
US10933067B2 (en) 2016-11-16 2021-03-02 National Center For Global Health And Medicine Nucleoside derivative having physiological activity such as antiviral activity
CN108203435B (zh) * 2016-12-16 2020-09-04 正大天晴药业集团股份有限公司 一种利用Boc保护基的恩替卡韦的制备方法
CN106749251A (zh) * 2017-01-17 2017-05-31 博瑞生物医药泰兴市有限公司 一种恩替卡韦中间体的合成与提纯方法
KR102197257B1 (ko) * 2017-10-19 2020-12-31 단국대학교 천안캠퍼스 산학협력단 엔테카비어 지방산 에스테르 유도체 수성현탁액의 안정화 조성물
CN109956975B (zh) * 2017-12-22 2020-11-06 浙江柏拉阿图医药科技有限公司 肝递送恩替卡韦前体药物核苷环磷酸酯化合物及应用
BR112021010351A2 (pt) * 2018-12-12 2021-08-31 Janssen Biopharma, Inc. Análogos de ciclopentil nucleosídeos como antivirais
CN113024574B (zh) * 2019-12-25 2024-03-29 南通诺泰生物医药技术有限公司 一种氧杂二环己烷类化合物的制备方法
CN111732589B (zh) * 2020-06-08 2021-07-30 王乔 一种改进的恩替卡韦中间体合成工艺以及改进的恩替卡韦合成工艺
CN112625041A (zh) * 2020-12-25 2021-04-09 常州博海威医药科技股份有限公司 恩替卡韦的新制备方法以及中间体
CN115433188B (zh) * 2022-09-29 2024-07-12 苏州东瑞制药有限公司 一种恩替卡韦的制备方法
CN115819422A (zh) * 2022-12-13 2023-03-21 淄博矿业集团有限责任公司 恩替卡韦中间体制备新工艺方法及分析方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164556B (sv) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US5063233A (en) * 1986-11-14 1991-11-05 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists
KR910008800B1 (ko) * 1987-03-19 1991-10-21 야마사 쇼오유 가부시끼가이샤 2'-알킬리덴 피리미딘 누클레오시드 유도체, 그 제조법, 및 그 용도
US4997925A (en) * 1987-08-26 1991-03-05 Merrell Dow Pharmaceuticals Inc. 5'-deoxy-5',5'-dihalo adenosines and purine analogues
NZ225906A (en) * 1987-08-26 1990-10-26 Merrell Dow Pharma Aristeromycin/adenosine derivatives and pharmaceutical compositions
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
DE68928127T2 (de) * 1988-08-25 1997-09-25 Yamasa Shoyu Kk 2'-Methylidenpyrimidinnukleosidverbindungen, ihre Verwendung und Verfahren zu ihrer Herstellung
HU204843B (en) * 1988-09-27 1992-02-28 Merrell Dow Pharma Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same
GB8916478D0 (en) * 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5064961A (en) * 1989-12-18 1991-11-12 E. R. Squibb & Sons, Inc. Process for preparing an optically active cyclobutane nucleoside
US5057630A (en) * 1990-04-06 1991-10-15 Glaxo Inc. Synthesis of cyclopentene derivatives

Also Published As

Publication number Publication date
ATE157095T1 (de) 1997-09-15
CA2053339C (en) 2001-05-29
DE69127336D1 (de) 1997-09-25
LU91275I2 (fr) 2007-06-16
EP0481754A3 (en) 1992-09-16
FI914928A0 (fi) 1991-10-18
CY2006008I2 (el) 2016-10-05
CN1030916C (zh) 1996-02-07
PL292101A1 (en) 1992-08-10
KR920008043A (ko) 1992-05-27
HK1001343A1 (en) 1998-06-12
DK0481754T3 (da) 1997-09-15
KR0160523B1 (ko) 1998-12-01
NO2006018I2 (no) 2008-10-20
HU913283D0 (en) 1992-01-28
PL169403B1 (pl) 1996-07-31
EP0481754A2 (en) 1992-04-22
CN1061972A (zh) 1992-06-17
DE122006000069I2 (de) 2012-04-19
HUT59109A (en) 1992-04-28
DE69127336T2 (de) 1998-01-02
JPH04282373A (ja) 1992-10-07
IL99755A0 (en) 1992-08-18
GR3025395T3 (en) 1998-02-27
FI914928A (fi) 1992-04-19
NO914089L (no) 1992-04-21
RU2037496C1 (ru) 1995-06-19
HU213207B (en) 1997-03-28
NL300241I1 (nl) 2006-12-01
CA2053339A1 (en) 1992-04-19
ES2104673T3 (es) 1997-10-16
NZ240053A (en) 1993-05-26
US5206244A (en) 1993-04-27
NO179906C (no) 1997-01-08
CY2063B1 (en) 1998-06-12
DE122006000069I1 (de) 2007-05-24
IE913451A1 (en) 1992-04-22
ZA917894B (en) 1993-03-31
AU634423B2 (en) 1993-02-18
EP0481754B1 (en) 1997-08-20
AU8559891A (en) 1992-04-30
JP2994117B2 (ja) 1999-12-27
NO179906B (no) 1996-09-30
SG70958A1 (en) 2000-03-21
CY2006008I1 (el) 2009-11-04
NO2006018I1 (no) 2006-12-27
PT99281B (pt) 1999-04-30
BR1100846A (pt) 2000-04-18
NO914089D0 (no) 1991-10-17
PT99281A (pt) 1992-08-31
IL99755A (en) 1996-08-04

Similar Documents

Publication Publication Date Title
FI109905B (sv) Förfarande för framställning av antivirala hydroximetyl(metylencyklopentyl)puriner och -pyrimidiner
KR0128661B1 (ko) 시클로부탄 유도체 및 그 제조 방법
FI101793B (sv) Förfarande för framställning av nya terapeutiskt användbara 9-purinylf osfonsyraderivat
US5059690A (en) Purinyl tetrahydrofurans
HU195657B (en) Process for production of carbocyclic pirin nucleorids and medical compounds containing them
CZ193489A3 (en) Bis(hydroxymethyl)cyclobutyl purines and pyrimidines, process of their preparation and use
KR0127137B1 (ko) 디데옥시디데히드로카르보시클릭 뉴클레오시드
US5817647A (en) Unsaturated acetylene phosphonate derivatives of purines
HU203236B (en) Process for producing purinyl and pyrimidinyl cyclobutanes
KR20000029952A (ko) 포스포네이트뉴클레오티드화합물
DE69419328T2 (de) Antivirale Tetrahydropyrane
AU6516294A (en) Unsaturated phosphonates derivatives of purines and pyrimidines
US4060616A (en) Purine derivatives with repeating unit
EP0394893B1 (en) Purinyl and pyrimidinyl tetrahydrofurans
US5340816A (en) Hydroxymethyl(methylenecyclopentyl) purines and pyrimidines
US10167302B2 (en) Phosphonate nucleosides useful in the treatment of viral diseases
US5145960A (en) Pyrimidinyl tetrahydrofurans
AU673259B2 (en) 3-hydroxy-4-hydroxymethyl-2-methylenecyclopentyl purines and pyrimidines
CN1031055C (zh) 二脱氧二脱氢碳环核苷的制备方法
GB2243609A (en) Carbocyclic nucleosides
JPH0491094A (ja) 新規なシクロブタン誘導体
JPH05178746A (ja) 抗ウイルス剤

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20060019

PC Transfer of assignment of patent

Owner name: E.R. SQUIBB & SONS, L.L.C.

Free format text: E.R. SQUIBB & SONS, L.L.C.

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 237

Extension date: 20161018

MA Patent expired
SPCE Application for extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: L20060019

SPCP Extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: 237

Extension date: 20170418